Click to go to DrugInjuryLaw Home


Legal information and news about prescription drug side effects
Avandia Case Evaluation Tequin Case Evaluation Ortho Evra Case EvaluationKetek Case Evaluation Fosamax Case Evaluation\ Permax Case Evaluation Zelnorm Case Evaluation Vytorin Case Evaluation
Dostinex Case Evaluation Bextra Case Evaluation NuvaRing Case Evalulation Natrecor Case Evaluation Crestor Case Evaluation Vioxx Case EvaluationDigitek Case Evaluation

Medical Device Alert: Medtronic Recalls Sprint Fidelis Heart Lead Wire

Free Case Evaluation

Crestor Should Be Used As Last Resort

FDA Official and UK Medicine Regulators Expressed Worries Over Crestor

AstraZeneca's cholesterol-lowering statin drug Crestor should only be used as a last resort, according to FDA's Dr. David Graham. Though statins have been associated with rhabdomyolysis in the past, according to Dr. Graham, Crestor has a "unique toxicity" in that adverse side effects include muscle wasting and kidney failure. "Crestor should only be used as a second line drug when people have failed to respond to other statins," says Dr. Graham.

Authorities at the UK Medicines and Healthcare Products Regulatory Agency (MHRA), when reviewing advice from experts at the Committee on Safety of Medicines (CSM), show that the original advice from CSM said the 40 mg dose of Crestor should not go on the market. Minutes of MHRA meetings reveal it has seen higher rates of rhabdomyolysis in patients on Crestor compared with other statin drugs.

There are a number of studies being conducted about the safety of Crestor and results should be published in 2005.

In May 2004, AstraZeneca sent a Dear Doctor letter to UK health professionals urging them to recommend the 10 mg dose for new patients when prescribing Crestor and Crestor's European label was changed in June 2004 due to safety concerns.

Read more on our Crestor Information Page >>


  • US FDA advises that you should not stop taking any prescription medication before talking to your doctor.
  • Reports of serious drug side effects should be made to the US FDA MedWatch program.
  • The prescription drug names are registered trademarks of the respective drug companies.
  • DrugInjuryLaw.com is not affiliated with any of the drug companies, nor US FDA.
Law Offices of Thomas J. Lamb, P.A.
Lumina Station Suite 225
1908 Eastwood Road
Wilmington, NC 28403
Tel: (910) 256-2971   Fax: (910) 256-2972
Toll Free: (800) 426-9535
email: ThomasJLamb@DrugInjuryLaw.com

Disclaimer